CollPlant Biotechnologies Ltd. has expanded its partnership with STEMCELL Technologies, a biotechnology company known for developing specialized cell culture media, tools, and services. This extended collaboration allows CollPlant's proprietary plant-derived recombinant human collagen (rhCollagen) to be utilized not only in research but also in clinical development and commercial-scale manufacturing. Yehiel Tal, CEO of CollPlant, highlighted the importance of this partnership in addressing the evolving needs of the life sciences market and emphasized the ethical and sustainable advantages of their plant-derived rhCollagen over traditional animal-sourced materials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO05775) on June 09, 2025, and is solely responsible for the information contained therein.